AI Engines For more Details: Perplexity Kagi Labs You
Antihistaminic Effects: Pheniramine maleate blocks the action of histamine, a substance in the body that contributes to allergic reactions. By inhibiting histamine receptors, pheniramine helps relieve symptoms such as sneezing, itching, watery eyes, and runny nose associated with allergies.
Allergic Rhinitis: Pheniramine maleate is commonly used to alleviate symptoms of allergic rhinitis, also known as hay fever. It can help reduce nasal congestion, sneezing, itching, and runny nose caused by exposure to allergens such as pollen, dust mites, or pet dander.
Allergic Conjunctivitis: Pheniramine maleate may be used to relieve symptoms of allergic conjunctivitis, an inflammation of the conjunctiva (the membrane covering the inner surface of the eyelids and the whites of the eyes) triggered by allergens. It can help alleviate itching, redness, and watering of the eyes.
Allergic Skin Reactions: Pheniramine maleate can be effective in managing allergic skin reactions, including itching, hives (urticaria), and insect bites. It works by reducing histamine-induced itching and inflammation, providing relief from discomfort and promoting healing of the affected skin.
Sedation: Pheniramine maleate has sedative properties and may cause drowsiness or sleepiness, particularly when taken at higher doses or in combination with other medications that have sedating effects. Patients should be cautioned against driving or operating machinery until they know how pheniramine affects them.
Central Nervous System Effects: In addition to sedation, pheniramine maleate may cause other central nervous system effects, such as dizziness, confusion, or impaired coordination. These effects are generally mild and transient but may be more pronounced in some individuals.
Dry Mouth: Pheniramine maleate can cause dryness of the mouth due to its anticholinergic effects, which reduce saliva production. Patients should stay well-hydrated and consider using sugar-free lozenges or chewing gum to alleviate dry mouth symptoms.
Urinary Retention: In rare cases, pheniramine maleate may cause urinary retention, particularly in men with prostatic hypertrophy or individuals with bladder obstruction. Patients should be monitored for urinary symptoms and advised to seek medical attention if they experience difficulty urinating.
Gastrointestinal Effects: Gastrointestinal side effects such as nausea, vomiting, or constipation may occur with pheniramine use, although they are relatively uncommon.
Cardiovascular Effects: Pheniramine maleate has minimal effects on the cardiovascular system, but caution should be exercised in patients with pre-existing cardiovascular conditions, as antihistamines may rarely cause changes in heart rate or blood pressure.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.4 | 0.17 |
| Allergies | 5.8 | 3.2 | 0.81 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.8 | 7.7 | -0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.3 | 7.67 |
| Ankylosing spondylitis | 3.6 | 1.8 | 1 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 5.9 | 2.3 | 1.57 |
| Atherosclerosis | 2.1 | 1.9 | 0.11 |
| Atrial fibrillation | 4.1 | 2.5 | 0.64 |
| Autism | 10.2 | 9.6 | 0.06 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 2.4 | 2.4 | |
| Bipolar Disorder | 1.8 | 1.7 | 0.06 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.4 | 2.6 | 0.69 |
| Celiac Disease | 3 | 3.8 | -0.27 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 6 | 7.7 | -0.28 |
| Chronic Kidney Disease | 4.6 | 2.9 | 0.59 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 2 | 0.2 |
| Chronic Urticaria (Hives) | 0.8 | 1.2 | -0.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 6.6 | 2.2 | 2 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 3 | -0.67 |
| COVID-19 | 10.3 | 13.8 | -0.34 |
| Crohn's Disease | 8.7 | 5.8 | 0.5 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 1.5 | 1.4 | 0.07 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 11.8 | 9.3 | 0.27 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.6 | -0.53 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.8 | 1.7 | 0.65 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4.9 | 0.16 |
| gallstone disease (gsd) | 3.1 | 1.1 | 1.82 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 2.2 | 2 | 0.1 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.5 | 3.2 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 3.9 | 1.8 | 1.17 |
| Heart Failure | 4.2 | 1.9 | 1.21 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 1.2 | 1.1 | 0.09 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.1 | 6.3 | -0.54 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 2.4 | 0.3 | 7 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 9.2 | 10.4 | -0.13 |
| Insomnia | 2.5 | 2.4 | 0.04 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 7.7 | 5.3 | 0.45 |
| ischemic stroke | 2.6 | 1.1 | 1.36 |
| Liver Cirrhosis | 7.5 | 3.6 | 1.08 |
| Long COVID | 7.7 | 8.8 | -0.14 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.5 | 3.2 |
| Metabolic Syndrome | 7.8 | 8.5 | -0.09 |
| Mood Disorders | 11.7 | 7.8 | 0.5 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 7.3 | 7 | 0.04 |
| Multiple system atrophy (MSA) | 1.2 | 0.7 | 0.71 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 1.6 | -1.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.3 | 4.8 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 10 | 8.9 | 0.12 |
| obsessive-compulsive disorder | 5.8 | 4.2 | 0.38 |
| Osteoarthritis | 2.7 | 1.2 | 1.25 |
| Osteoporosis | 1.9 | 1.3 | 0.46 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 7.7 | 7.7 | 0 |
| Polycystic ovary syndrome | 7.3 | 3.2 | 1.28 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 3.3 | 3.4 | -0.03 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.5 | 4.7 | 0.81 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.2 | 3.1 | 1.32 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 2.6 | 2.7 | -0.04 |
| Systemic Lupus Erythematosus | 4.3 | 2.4 | 0.79 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.9 | 4.4 | -0.13 |
| Type 2 Diabetes | 8.8 | 7.3 | 0.21 |
| Ulcerative colitis | 5.8 | 7.7 | -0.33 |
| Unhealthy Ageing | 6.8 | 2.4 | 1.83 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
